J&J gets into psychedelic treatments with backing of Delix Therapeutics (JNJ:NYSE)
· seekingalpha.com
Johnson & Johnson backs Delix in a $100M funding round to advance a psychedelic-inspired depression drug.
Search field
Entering text into the input field will update the search result below